In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 101 to 125 of 303

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Eplontersen for treating hereditary transthyretin-related amyloidosis [ID6337]	Technology appraisal guidance	27 November 2024
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]	Technology appraisal guidance	TBC
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]	Technology appraisal guidance	26 February 2025
Evobrutinib for treating relapsing multiple sclerosis [ID6313]	Technology appraisal guidance	TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920	Technology appraisal guidance	TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]	Technology appraisal guidance	TBC
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]	Technology appraisal guidance	TBC
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]	Technology appraisal guidance	21 May 2025
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]	Technology appraisal guidance	TBC
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]	Technology appraisal guidance	TBC
Fruquintinib for previously treated metastatic colorectal cancer ID6274	Technology appraisal guidance	5 March 2025
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]	Technology appraisal guidance	TBC
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]	Technology appraisal guidance	25 June 2025
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]	Technology appraisal guidance	TBC
Glaucoma - lerdelimumab (CAT-152) [ID383]	Technology appraisal guidance	TBC
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]	Technology appraisal guidance	TBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238	Technology appraisal guidance	TBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237	Technology appraisal guidance	TBC
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]	Technology appraisal guidance	TBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]	Technology appraisal guidance	30 April 2025
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]	Technology appraisal guidance	TBC
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]	Technology appraisal guidance	23 April 2025
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]	Technology appraisal guidance	TBC
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]	Technology appraisal guidance	TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992]	Technology appraisal guidance	TBC

Results per page

10
25
50
All